/Investor DB

AbbVie — 2025 Investments

1 investments dated 2025 · listed companies and verified rows first · show all

Stylus Medicinestylusmedicine.cominSeries A · May 2025 · $85M

Stylus Medicine develops in vivo genetic medicines using engineered recombinases, with initial focus on creating CAR-T therapies delivered via lipid nanoparticles for oncology, autoimmune, and genetic diseases.

BiotechDigital HealthMedical Devices

Michael C. Bassik, Ph.D.(Scientific Founder)Emile Nuwaysir, Ph.D.(Chairman & Chief Executive Officer)inJason Fontenot, Ph.D.(Chief Scientific Officer)Ami Bhatt(Founder)Lacramioara Bintu(Founder)Michael Bassik(Founder)

Co-investorsBrainstorm VenturesCAL InnovationCalifornia Innovation FundKhosla VenturesNeva Sgr.RA Capital+1 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.